An efficient copper-mediated tandem C(sp2)–H amination to provide quinazolinones from N-(quinolin-8-yl)benzamide and amidine hydrochlorides has been developed. It can afford rather complex products in a single step synthesis from easily available starting materials using 8-aminoquinoline as a removable bidentate directing group. The features of this reaction are it being simple to operate and avoiding
An efficient Pd(ii)-catalyzed direct O-alkenylation of 2-arylquinazolinones with simple ketone-derived N-tosylhydrazones is reported.
报道了一种高效的Pd(II)催化的直接2-芳基喹唑酮与简单酮衍生的N-对甲苯磺酰肼烯烃化反应。
Synthesis of 2-aryl quinazolinones <i>via</i> iron-catalyzed cross-dehydrogenative coupling (CDC) between N–H and C–H bonds
作者:Yoonkyung Jang、Seok Beom Lee、Junhwa Hong、Simin Chun、Jeeyeon Lee、Suckchang Hong
DOI:10.1039/d0ob00866d
日期:——
describe the direct synthesis of quinazolinones via cross-dehydrogenative coupling between methylarenes and anthranilamides. The C–H functionalization of the benzylic sp3 carbon is achieved by di-t-butyl peroxide under air, and the subsequent amination–aerobic oxidation process completes the annulation process. Iron catalyzed the whole reaction process and various kinds of functional groups were tolerated
[EN] THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS<br/>[FR] DERIVES DE THIENOPYRIMIDINE ET THIENOPYRIDINE UTILES COMME AGENTS ANTICANCEREUX
申请人:PFIZER PRODUCTS INC.
公开号:WO1999024440A1
公开(公告)日:1999-05-20
(EN) The invention relates to compounds of formulas (1) and (2) and to pharmaceutically acceptable salts and hydrates thereof, wherein X1, R1, R2 and R11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas (1) and (2) and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas (1) and (2).(FR) L'invention concerne des composés représentés par les formules (1) et (2), et des sels et hydrates pharmaceutiquement acceptables de ces composés. X1, R1, R2 et R11 sont tels que définis dans le descriptif. L'invention concerne en outre des compositions pharmaceutiques contenant les composés des formules (1) et (2) ainsi que des traitements de troubles hyperprolifératifs chez le mammifère, comprenant l'administration des composés des formules (1) et (2).